Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study. (linkinghub.elsevier.com)

Authors: Colombo N … Wu X Journal: The Lancet Published: 2026-04-18 DOI: https://doi.org/10.1016/S0140-6736(26)00602-1